Status update from CombiGene’s CEO
With the first quarter of the year concluded, CombiGene’s CEO Jan Nilsson visited BioStock’s studio for a status update on the gene therapy company’s project. Nilsson not only talks about the pain project COZY and the epilepsy candidate CG01, but also about the company’s financial status.
See the interview with CombiGene’s CEO Jan Nilsson below.
Read more about CombiGene here.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.
